Browse EX-10 agreements

---

Exhibit 10.35

Portions of this exhibit, indicated by [***], have been omitted in accordance with Item 601(b)(10) (iv) of Regulation S-K. The omitted information is (i) not material and (ii) treated by the Registrant as private or confidential.

Portions of this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K.

The Registrant undertakes to furnish a copy of all omitted information, schedules, and exhibits to the U.S. Securities and Exchange Commission upon its request.

TEMPUS

Master Agreement

This Master Agreement (the “Agreement”) is entered into by and between Tempus Labs, Inc., with its principal place of business at 600 West Chicago Ave., Suite 510, Chicago, IL 60654 (on behalf of itself and its affiliates, “Tempus”) and Remix Therapeutics Inc., with its principal place of business at 100 Forge Road, Watertown MA 02472 (“Client”). Tempus and Client are each individually a “Party” and are collectively the “Parties.”

Background

…

---

Exhibit 10.30

Portions of this exhibit, indicated by [***], have been omitted in accordance with Item 601(b)(10) (iv) of Regulation S-K. The omitted information is (i) not material and (ii) treated by the Registrant as private or confidential.

Portions of this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K.

The Registrant undertakes to furnish a copy of all omitted information, schedules, and exhibits to the U.S. Securities and Exchange Commission upon its request.

---

*
*

LEASE

From

100 FORGE HOLDING LLC,

Landlord

To

REMIX THERAPEUTICS INC.,

Tenant

100 Forge Road, Watertown, Massachusetts

---

TABLE OF CONTENTS

Page

…

---

Exhibit 10.32

REMIX THERAPEUTICS, INC.

25th July 2019

PERSONAL AND CONFIDENTIAL

Dear Dominic

Remix Therapeutics, Inc. (the “Company”) is pleased to offer you the full-time position of Vice President.  We are excited about the prospect of you joining our team, and look forward to the addition of your professionalism and experience to help the Company achieve its goals.  As a full-time employee, you are expected to devote your full time and best efforts to the Company, and you may not engage in outside business activities without the Company’s prior written consent.  Notwithstanding the foregoing, the Company acknowledges that, in the first year of your employment, you may engage in consulting or other business activities for other portfolio companies of Atlas Ventures (“Atlas”) up to a maximum of 25% of your business time, with the prior agreement of the Chief Scientific Officer.

…

---

Exhibit 10.1

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO TREELINE BIOSCIENCES, INC. IF PUBLICLY DISCLOSED.

DATED          20 May          2022

(1)          CRT PIONEER FUND LP

AND

(2)          TREELINE BIOSCIENCES, INC.

LICENCE AGREEMENT

1

---

THIS AGREEMENT is made the 20th day of May 2022

BETWEEN:

| | |

…

---

Exhibit 10.3

AMENDED AND RESTATED THIRD AMENDMENT TO LEASE

THIS AMENDED AND RESTATED THIRD AMENDMENT TO LEASE AMENDS, RESTATES AND SUPERSEDES IN ITS ENTIRETY THAT CERTAIN THIRD AMENDMENT TO LEASE DATED MAY 10, 2024, BY AND BETWEEN LANDLORD AND TENANT.

THIS AMENDED AND RESTATED THIRD AMENDMENT TO LEASE (this “Third Amendment”) is made as of May 23, 2024, by and between ARE-500 ARSENAL STREET, LLC, a Delaware limited liability company (“Landlord”), and TREELINE BIOSCIENCES, INC., a Delaware corporation (“Tenant”).

RECITALS

…

---

Exhibit 10.2

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO TREELINE BIOSCIENCES, INC. IF PUBLICLY DISCLOSED.

EXCLUSIVE LICENSE AGREEMENT

This EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of February 9, 2023 (the “Effective Date”), by and between TREELINE BIOSCIENCES, INC., a Delaware corporation with an office at 677 Washington Blvd., Ste 525, Stamford, Connecticut 06901, U.S.A. (“Treeline”) and JIANGSU HENGRUI PHARMACEUTICALS CO., LTD., a Chinese corporation with offices at 7 Kunlunshan Road, Economy and Technology Development Zone, Lianyungang, Jiangsu, P.R.C. (“Hengrui”). Treeline and Hengrui are referred to individually as a “Party” and collectively as the “Parties.”

RECITALS

WHEREAS, Treeline is a pharmaceutical company in the business of developing and commercializing therapeutic products;

…

**Exhibit 10.34 **

**AVENZO THERAPEUTICS, INC. **

August 22, 2022

Mohammad Hirmand, M.D.

[***]

Re:	**Employment Terms **

Dear Mohammad:

Avenzo Therapeutics, Inc. (the “Company”) is pleased to offer you at-will employment in the position of Executive Vice President and Chief Medical Officer on the terms and conditions set forth in this letter agreement (the “Agreement”).

…

**Exhibit 10.33 **

**AVENZO THERAPEUTICS, INC. **

August 22, 2025

Athena M. Countouriotis, M.D.

[***]

Re:	**Employment Terms **

Dear Athena:

This letter agreement (the “Agreement”) is effective as of August 22, 2025 (the “Effective Date”) and amends and restates that certain letter agreement between you and Avenzo Therapeutics, Inc. (the “Company”) dated August 18, 2022 (the “Prior Agreement”). The terms of this Agreement supersede the terms of the Prior Agreement in their entirety.

…

**Exhibit 10.38 **

**CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE AVENZO THERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO AVENZO THERAPEUTICS, INC. IF PUBLICLY DISCLOSED. **

**AMENDMENT NO.1 TO COLLABORATION, EXCLUSIVE OPTION AND LICENSE AGREEMENT **

This AMENDMENT NO.1 TO COLLABORATION, EXCLUSIVE OPTION AND LICENSE AGREEMENT (this “Amendment”) is entered into as of November 26, 2024 (the “Amendment Effective Date”) by and between Avenzo Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (“Avenzo”), with offices located at 12707 High Bluff Drive, Suite 200, San Diego, California 92130, United States, and VelaVigo (Shanghai) Limited, a corporation organized and existing under the laws of China (“VelaVigo”), with offices located at Building 1, 215 Fute South Rd, WGQ Free Trade Zone, Pudong, Shanghai, and for purposes of Sections 5.8 and 5.9, Article 18 and Article 19 of the License Agreeme

…

**Exhibit 10.35 **

**AVENZO THERAPEUTICS, INC. **

August 22, 2022

Brian Sun

[***]

Re:	**Employment Terms **

Dear Brian:

Avenzo Therapeutics, Inc. (the “Company”) is pleased to offer you at-will employment in the position of Senior Vice President, Chief Legal Officer and Corporate Secretary on the terms and conditions set forth in this letter agreement (the “Agreement”).

…

**Exhibit 10.39 **

**CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE AVENZO THERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO AVENZO THERAPEUTICS, INC. IF PUBLICLY DISCLOSED. **

**COLLABORATION AND LICENSE AGREEMENT **

**by and between **

AVENZO THERAPEUTICS, INC.

**and **

**DUALITY BIOLOGICS (SUZHOU) CO., LTD. **

**dated as of December 23, 2024 **

---

**TABLE OF CONTENTS **

…

**Exhibit 10.36 **

**CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE AVENZO THERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO AVENZO THERAPEUTICS, INC. IF PUBLICLY DISCLOSED. **

**COLLABORATION AND LICENSE AGREEMENT **

**by and between **

AVENZO THERAPEUTICS, INC.

**and **

ALLORION THERAPEUTICS INC.

**dated as of January 3, 2024 **

---

**TABLE OF CONTENTS **

…